No definition available.
Drug-induced systemic lupus erythematosus
DRUGADVERS_SYSTEMIC_LUPUS_ERYTHEMAT
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
239 |
4. Check minimum number of eventsNone |
239 |
5. Include endpointsNone |
239 |
6. Filter based on genotype QC (FinnGen only) |
239 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- C
- First used in FinnGen datafreeze
- DF5
Similar endpoints
↥List of similar endpoints to
Drug-induced systemic lupus erythematosus
based on the number of shared cases.
Similar with more cases:
- Systemic lupus erythematosus
- SLE (Finngen)
- Systemic connective tissue disorders
- Autoimmune diseases related-to ILD
- Finngen Rheumatological endpoints
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1257 | 1021 | 229 |
| Only index persons | 1098 | 918 | 180 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.03 | 0.01 |
| Only index persons | 0.03 | 0.03 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 52.81 | 51.34 | 58.87 |
| Only index persons | 50.83 | 49.95 | 55.29 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 239 | 201 | 38 |
| Unadjusted period prevalence (%) | 0.06 | 0.07 | 0.02 |
| Median age at first event (years) | 46.86 | 46.11 | 50.86 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 226
- Matched controls
- 2258
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M32.0
ICD-10 Finland
Drug-induced systemic lupus erythematosus
+∞
323.0
225
*
M32.9
ICD-10 Finland
Systemic lupus erythematosus, unspecified
1482.2
213.1
175
5
P01BA02
ATC
hydroxychloroquine; oral
68.7
141.3
170
95
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
39.7
114.4
159
127
M32.8
ICD-10 Finland
Other forms of systemic lupus erythematosus
1320.2
92.7
84
*
M32.1
ICD-10 Finland
Systemic lupus erythematosus with organ or system involvement
+∞
88.5
79
*
L04AX01
ATC
azathioprine; systemic
30.9
67.3
92
49
M32
ICD-10 Finland
Systemic lupus erythematosus
553.8
47.1
45
*
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
17.7
46.8
77
64
H02AB06
ATC
prednisolone; systemic
8.7
44.7
182
730
H02AB07
ATC
prednisone; oral
9.6
44.3
107
194
7100A
ICD-9 Finland
Diffuse diseases of connective tissue, Systemic lupus erythematosus
508.1
43.8
42
*
M35.9
ICD-10 Finland
Systemic involvement of connective tissue, unspecified
56.4
42.1
49
11
L04AA06
ATC
mycophenolic acid; systemic
48.9
41.8
50
13
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
7.2
41.5
156
533
L04AX03
ATC
methotrexate; systemic (immunosuppressants)
11.9
37.4
74
89
M05BA04
ATC
alendronic acid; oral
11.8
36.4
72
86
L93.0
ICD-10 Finland
Discoid lupus erythematosus
374.2
32.8
32
*
M35.0
ICD-10 Finland
Sicca syndrome [Sjögren]
28.4
32.4
44
19
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
12.3
29.7
56
59
N08.5*M32.1
ICD-10 Finland
Glomerular disorders in systemic lupus erythematosus
+∞
28.8
27
*
NK6QA
NOMESCO Finland
Measurement of bone density from tow or more locations with X-ray
8.7
27.2
63
96
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
8.2
26.8
65
106
L01BA01
ATC
methotrexate; systemic (folic acid analog.)
14.9
25.9
44
36
73410
ICD-8 Finland
Diffuse diseases of connective tissue, Systemic lupus erythematosus
+∞
25.5
24
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
4.4
24.5
141
618
G05.8*M32.1
ICD-10 Finland
Encephalitis in systemic lupus erythematosus
+∞
22.2
21
*
C08CA05
ATC
nifedipine; systemic
9.7
21.0
44
55
M35.1
ICD-10 Finland
Other overlap syndromes
121.3
21.0
22
*
D68.8
ICD-10 Finland
Other specified coagulation defects
50.9
19.6
23
5
G73.7*M32.1
ICD-10 Finland
Myopathy in systemic lupus erythematosus
+∞
19.0
18
*
TPH04
NOMESCO Finland
Cathetrisation of vein
4.3
18.9
86
285
R50.9
ICD-10 Finland
Fever, unspecified
5.2
18.7
65
164
L88
ICPC
Rheumatoid/seropositive arthritis
11.9
17.9
33
32
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
9.6
17.8
37
45
B01AA03
ATC
warfarin; systemic
4.9
17.4
64
170
ZX120
NOMESCO Finland
Intravenous
5.8
16.7
50
105
M05BA07
ATC
risedronic acid; oral
15.2
16.5
27
20
A02BC02
ATC
pantoprazole; systemic
3.7
16.2
179
1149
L04AA01
ATC
[U] ciclosporin; systemic
19.0
16.0
24
14
H02AB04
ATC
methylprednisolone; systemic
4.2
15.6
67
206
N02AX02
ATC
tramadol; systemic, rectal
3.0
14.0
125
660
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.2
13.9
94
409
E000001
ATC
NA
3.4
13.7
79
305
A02BC03
ATC
lansoprazole; oral
3.1
13.4
95
426
J18.9
ICD-10 Finland
Pneumonia, unspecified
3.7
13.3
65
220
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
2.9
13.1
127
695
Z01.0
ICD-10 Finland
Examination of eyes and vision
3.8
13.0
62
206
Z01.8
ICD-10 Finland
Other specified special examinations
3.3
12.8
78
312
D07AB08
ATC
desonide; topical
4.3
12.7
50
139
A49.9
ICD-10 Finland
Bacterial infection, unspecified
5.3
12.7
40
88
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
4.8
12.7
44
108
J01MA12
ATC
levofloxacin; systemic
3.7
12.5
61
205
C03CA01
ATC
furosemide; systemic
3.2
12.5
78
318
E0000UV
ATC
NA
2.8
12.2
118
633
J05AB01
ATC
aciclovir; systemic
3.2
12.2
78
320
P01BA01
ATC
chloroquine; systemic
49.5
12.0
14
*
XX9XE
NOMESCO Finland
Other ultrasound examination
31.9
11.8
15
5
A07AA02
ATC
nystatin; oral
5.6
11.8
35
72
B01AB05
ATC
enoxaparin; parenteral
2.9
11.7
93
442
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.8
11.5
52
164
L04AD01
ATC
ciclosporin; systemic
13.7
11.4
19
15
N02AJ06
ATC
codeine and paracetamol; systemic
2.7
11.1
106
557
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
3.2
10.2
62
241
XF400
NOMESCO Finland
ECG with 12 standard connections
3.4
10.1
54
192
J05AB11
ATC
valaciclovir; oral
3.5
9.9
49
165
D69.3
ICD-10 Finland
Idiopathic thrombocytopenic purpura
57.5
9.7
11
*
J01FA06
ATC
roxithromycin; oral
2.5
9.7
120
713
J99.1*M32.1
ICD-10 Finland
Respiratory disorders in systemic: lupus erythematosus
+∞
9.4
9
*
AA1AD
NOMESCO Finland
CT of head and brain
2.9
9.4
67
289
A02BC01
ATC
omeprazole; systemic
2.6
9.3
81
396
M05BB03
ATC
alendronic acid and colecalciferol; oral
10.7
9.2
17
17
O99.89
ICD-10 Finland
Other specified diseases and conditions complicating pregnancy, childbirth and the puerperium
16.5
9.2
14
9
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
4.0
9.1
37
105
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
3.5
9.1
45
151
J01FF01
ATC
clindamycin; systemic
2.6
9.1
85
428
J01MA02
ATC
ciprofloxacin; systemic
2.4
8.9
99
548
M05BA01
ATC
etidronic acid; systemic
52.1
8.7
10
*
R06.0
ICD-10 Finland
Dyspnoea
2.7
8.6
69
319
KA3AT
NOMESCO Finland
Biopsy of kidney with ultrasound guidance
21.0
8.6
12
6
N08.5
ICD-10 Finland
Glomerular disorders in systemic connective tissue disorders
+∞
8.4
8
*
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
3.1
8.3
50
192
ND2DA
NOMESCO Finland
Bilateral hand X-ray examination
8.7
8.2
17
21
I15.1
ICD-10 Finland
Hypertension secondary to other renal disorders
34.7
8.1
10
*
EBA10
NOMESCO Finland
Surgical removal of tooth
3.6
8.0
37
118
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
5.7
7.9
22
42
J01MA14
ATC
moxifloxacin; systemic
3.7
7.9
34
102
H26.3
ICD-10 Finland
Drug-induced cataract
46.6
7.8
9
*
FN1AC
NOMESCO Finland
Angiography of heart and/or coronary arteries
2.9
7.7
50
201
N02AA59
ATC
codeine, combinations excl. psycholeptics; systemic
2.2
7.5
117
743
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
4.1
7.5
29
79
SAA03
NOMESCO Finland
Extended examination of mouth
2.2
7.5
109
672
M05BX04
ATC
denosumab; parenteral
4.7
7.3
24
56
H04.10
ICD-10 Finland
Dry eye syndrome
3.3
7.3
36
121
B02.9
ICD-10 Finland
Zoster without complication
4.5
7.3
25
61
C02CA01
ATC
prazosin; oral
31.1
7.2
9
*
Z01.5
ICD-10 Finland
Diagnostic skin and sensitization tests
3.3
7.2
36
122
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
5.3
7.2
21
43
B01AB04
ATC
dalteparin; parenteral
5.3
7.2
21
43
R07.4
ICD-10 Finland
Chest pain, unspecified
2.4
7.1
68
342
Z50.1
ICD-10 Finland
Other physical therapy
4.5
7.1
24
58
N02BE01
ATC
paracetamol; systemic, rectal
3.0
7.0
205
1722
I63.9
ICD-10 Finland
Cerebral infarction, unspecified
3.9
7.0
28
79
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
7.1
6.9
16
24
L04AA13
ATC
leflunomide; oral
8.7
6.9
14
17
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
3.5
6.9
32
102
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
3.2
6.9
36
126
L99
ICPC
Musculoskeletal disease other
7.6
6.8
15
21
M80.4
ICD-10 Finland
Drug-induced osteoporosis with pathological fracture
41.3
6.8
8
*
R4120
NOMESCO Finland
Occupational therapy
3.8
6.7
27
77
R59.1
ICD-10 Finland
Generalized enlarged lymph nodes
12.8
6.7
11
9
L27.0
ICD-10 Finland
Generalized skin eruption due to drugs and medicaments
10.5
6.6
12
12
A02BA02
ATC
ranitidine; systemic
2.5
6.6
55
257
Y83
ICD-10 Finland
Surgical operation and other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
3.7
6.5
28
84
XPX99
NOMESCO Finland
Other diagnostic examination of periferal vessel
4.1
6.5
24
63
D07AC01
ATC
betamethasone; topical
2.1
6.5
90
534
T81.4
ICD-10 Finland
Infection following a procedure, not elsewhere classified
3.1
6.5
36
130
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
4.9
6.5
20
44
SPAT1148
SPAT
Treatment of chronic ulcer or burn
3.0
6.4
37
139
Z96.1
ICD-10 Finland
Presence of intraocular lens
3.3
6.4
32
109
A01AC01
ATC
triamcinolone; local oral
11.5
6.4
11
10
D69.6
ICD-10 Finland
Thrombocytopenia, unspecified
11.5
6.4
11
10
318
Kela drug reimbursment
Teriparatide
18.7
6.3
9
5
SPAT1325
SPAT
Vaccination
2.2
6.3
81
465
N05.8
ICD-10 Finland
Unspecified nephritic syndrome, other
+∞
6.3
6
*
N16.4*M32.1
ICD-10 Finland
Renal tubulo-interstitial disorders in systemic lupus erythematosus
+∞
6.3
6
*
7108X
ICD-9 Finland
Diffuse diseases of connective tissue, Other specified diffuse diseases of connective tissue
+∞
6.3
6
*
QX2XE
NOMESCO Finland
Ultrsound examination of soft tissue not elsewhere classified
6.1
6.3
16
28
N32.9
ICD-10 Finland
Bladder disorder, unspecified
27.5
6.3
8
*
1XC02
NOMESCO Finland
NA
27.5
6.3
8
*
QDB10
NOMESCO Finland
Major dressing of wound of skin of lower limb
4.7
6.2
20
46
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
3.9
6.2
24
66
UGC12
NOMESCO Finland
Flexible bronchoscopy
4.1
6.2
23
61
I69.3
ICD-10 Finland
Sequelae of cerebral infarction
4.4
6.2
21
51
C09AA02
ATC
enalapril; systemic
2.6
6.2
47
206
205
Kela drug reimbursment
Chronic hypertension
2.3
6.2
61
310
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
3.6
6.2
27
83
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
3.1
6.1
34
123
J02AC01
ATC
fluconazole; systemic
2.0
6.1
127
882
X59
ICD-10 Finland
Exposure to unspecified factor
2.5
6.1
52
245
A02BC05
ATC
esomeprazole; systemic
2.0
6.1
105
678
N03AX16
ATC
pregabalin; oral
2.2
6.0
66
351
WZB00
NOMESCO Finland
Telephone receipt or other advice
2.1
6.0
79
453
S97
ICPC
Chronic ulcer skin
4.7
6.0
19
43
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
113
84
24.62
130.49
8.7
2.0
—
—
—
0
0
77
67
16.48
78.99
1.8
1.3
21.9
2.9
u/ml
—
22
10
76
68
15.92
76.56
1.8
1.3
12.1
9.0
u/ml
0.18
28
15
77
72
15.30
75.45
1.8
1.3
32.6
1.2
u/ml
—
14
5
64
53
16.13
67.02
1.7
1.3
2.2
1.0
u/ml
—
8
5
72
86
11.55
59.07
1.9
1.3
0.9
2.0
u/ml
—
7
5
57
60
12.16
50.72
1.7
1.3
52.3
34.5
u/ml
—
20
9
44
35
15.18
46.49
1.7
1.2
7.5
1.5
u/ml
1.23
30
11
43
39
13.23
41.86
1.8
1.1
7.7
5.3
u/ml
0.28
26
14
34
23
17.07
39.01
1.6
1.2
—
—
—
0
0
34
23
17.07
39.01
1.6
1.2
—
—
—
0
0
34
24
16.35
38.13
1.6
1.2
—
—
—
0
0
34
24
16.35
38.13
1.6
1.2
—
—
—
0
0
34
24
16.35
38.13
1.6
1.2
—
—
—
0
0
208
1176
6.93
27.89
21.1
9.1
3.6
3.9
e9/l
1.98
200
1038
172
872
4.47
25.62
3.6
2.3
80.1
77.6
nmol/l
0.57
166
787
68
186
4.71
23.69
3.9
4.6
257.8
245.2
u/l
0.39
68
179
80
250
4.31
23.42
4.2
2.2
2.2
2.5
g/l
3.85
80
230
175
939
4.23
23.05
12.7
6.0
1.2
1.2
mmol/l
0.22
159
793
75
234
4.21
21.85
4.3
2.3
21.7
22.6
%
0.22
67
200
140
666
3.66
21.71
7.9
2.9
—
—
—
0
0
119
512
3.64
21.57
7.1
2.7
0.1
0.4
e6/l
1.65
97
378
80
281
3.78
19.45
4.1
2.2
11.5
14.1
umol/l
2.38
80
257
22
23
10.43
19.07
1.6
1.1
—
—
—
0
0
175
1018
3.69
18.65
11.3
4.6
0.0
0.0
estimate
0.00
39
193
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
25
32
8.61
18.64
4.5
5.8
0.3
0.4
u/ml
0.57
14
22
173
1007
3.60
18.24
7.7
3.4
0.0
0.0
estimate
0.00
38
198
174
1029
3.54
17.61
7.8
3.4
0.0
0.0
estimate
0.00
37
186
53
152
4.20
16.98
6.3
4.2
1.9
2.1
mmol/l
0.12
48
122
17
15
12.12
16.38
1.4
1.2
—
—
—
0
0
147
813
3.10
16.15
8.2
3.9
34.4
36.2
g/l
3.82
142
766
14
11
13.46
14.37
1.6
1.5
—
—
—
0
0
31
67
5.17
13.98
2.0
1.6
—
—
—
0
0
73
301
3.05
13.12
6.4
2.5
0.6
1.0
e6/l
1.59
45
161
93
446
2.78
12.57
4.2
2.1
2.9
3.2
mg/l
0.48
88
379
21
35
6.48
12.35
1.3
1.4
—
—
—
0
0
27
58
5.12
12.22
1.8
1.7
0.0
0.0
iu/ml
—
7
6
68
281
2.98
12.07
6.9
2.7
1.9
3.4
e6/l
0.95
41
141
210
1551
3.92
11.99
14.2
4.0
15.6
10.9
mm/h
5.31
204
1434
23
44
5.68
11.79
1.7
2.0
—
—
—
0
0
65
268
2.96
11.53
2.6
1.8
—
—
—
0
0
51
184
3.25
11.37
2.6
1.7
—
—
—
0
0
50
186
3.13
10.55
2.7
1.7
—
—
—
0
0
102
554
2.47
10.28
7.4
3.7
22.0
9.6
mg/mmol
1.01
80
317
11
10
11.48
10.23
1.2
1.0
—
—
—
0
0
90
467
2.49
9.96
2.9
1.8
1.3
0.9
mg/l
0.77
77
357
37
128
3.24
8.74
1.8
1.5
—
—
—
0
0
10
10
10.39
8.70
1.6
2.5
—
—
—
0
0
10
10
10.39
8.70
1.6
2.5
—
—
—
0
0
90
492
2.33
8.65
3.5
3.2
1405.5
866.6
ng/l
0.74
82
413
12
16
7.84
8.49
1.2
1.3
2.1
2.0
mmol/l
0.10
12
16
21
50
4.51
8.38
1.5
1.2
—
—
—
0
0
19
42
4.83
8.28
1.7
1.3
—
—
—
0
0
20
47
4.55
8.11
2.0
2.2
—
—
—
0
0
19
44
4.60
7.84
5.5
3.7
62.2
62.2
%
0.01
19
44
81
445
2.24
7.52
3.0
2.2
—
—
—
0
0
11
16
7.16
7.21
1.2
1.1
—
—
—
0
0
16
35
4.83
7.04
1.8
1.5
—
—
—
0
0
10
14
7.41
6.75
1.1
1.2
—
—
—
0
0
64
332
2.27
6.74
6.7
3.4
374.2
134.8
ng/l
0.91
51
237
16
37
4.56
6.60
1.3
1.5
—
—
—
0
0
135
936
2.02
6.53
5.1
2.7
182.1
90.6
ug/l
1.75
130
876
16
38
4.44
6.39
1.1
1.4
—
—
—
0
0
116
767
2.00
6.38
2.2
1.9
97.3
99.8
pmol/l
0.22
58
370
17
44
4.08
6.10
5.2
3.2
3.7
4.9
e9/l
1.71
17
44
147
1072
1.96
5.92
7.1
5.6
9.8
10.1
umol/l
0.14
142
1006
44
205
2.41
5.87
10.3
5.1
105.6
103.6
mmol/l
2.33
44
197
45
213
2.37
5.80
51.5
18.6
1.5
1.3
inr
—
7
31
17
46
3.90
5.75
1.4
1.6
—
—
—
0
0
17
47
3.82
5.59
1.8
1.7
80.9
225.6
ug/l
1.79
17
42
10
18
5.75
5.37
1.1
1.0
—
—
—
0
0
10
18
5.75
5.37
1.2
1.1
—
—
—
0
0
11
23
4.97
5.06
1.4
1.5
—
—
—
0
0
25
95
2.82
5.00
2.1
1.6
—
—
—
0
0
16
46
3.66
4.99
1.6
1.5
—
—
—
0
0
58
324
2.04
4.93
1.6
1.7
1163.5
1274.1
nmol/l
0.49
49
244
104
707
1.83
4.91
4.2
3.3
32.0
29.8
ng/l
0.08
77
427
114
798
1.82
4.89
8.4
3.5
—
—
—
0
0
130
952
1.80
4.75
5.5
3.8
—
—
—
0
0
23
86
2.85
4.74
2.2
3.7
25.9
24.8
mmol/l
0.83
23
86
39
191
2.25
4.62
9.9
5.6
-0.2
1.3
mmol/l
1.04
33
151
11
25
4.56
4.61
1.3
1.5
—
—
—
0
0
7
5
14.36
4.60
1.0
1.4
—
—
—
0
0
15
44
3.57
4.54
1.4
1.7
—
—
—
0
0
71
437
1.89
4.53
1.8
1.4
21.2
21.8
nmol/l
0.13
64
366
12
30
4.16
4.49
1.3
1.5
—
—
—
0
0
17
55
3.25
4.46
1.6
1.3
—
—
—
0
0
9
12
7.74
4.39
1.2
1.3
—
—
—
0
0
10
22
4.70
4.34
1.1
1.6
—
—
—
0
0
10
23
4.49
4.13
1.6
1.2
—
—
—
0
0
13
37
3.66
4.11
1.6
1.2
—
—
—
0
0
13
37
3.66
4.11
1.6
1.2
—
—
—
0
0
17
58
3.08
4.10
1.4
1.1
—
—
—
0
0
9
14
6.63
4.02
1.0
1.1
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
7
8
8.97
3.80
1.3
1.3
—
—
—
0
0
7
8
8.97
3.80
1.9
2.3
—
—
—
0
0
96
680
1.69
3.69
3.5
3.1
2.3
2.4
mmol/l
1.09
89
597
81
550
1.72
3.62
7.8
3.8
0.0
0.0
estimate
0.00
39
194
76
507
1.73
3.62
1.4
1.3
0.6
1.7
u/ml
0.87
16
161
96
683
1.68
3.61
4.2
3.0
28.9
29.2
u/l
0.04
89
651
9
17
5.45
3.54
2.3
1.3
—
—
—
0
0
8
13
6.32
3.53
1.5
1.8
13.6
12.5
umol/l
—
8
13
6
7
8.75
3.28
1.2
1.3
—
—
—
0
0
23
104
2.34
3.28
6.5
4.0
0.7
1.7
mmol/l
0.33
18
83
67
444
1.71
3.23
6.9
3.6
1.0
1.0
kg/l
3.51
11
55
19
79
2.53
3.23
3.7
3.6
39.1
51.1
%
1.08
19
79
9
20
4.63
3.14
1.1
1.3
—
—
—
0
0
62
406
1.71
3.11
1.4
1.3
12.1
8.8
u/ml
0.17
27
166
21
94
2.35
3.06
2.0
1.4
—
—
—
0
0
22
101
2.30
3.04
7.3
5.6
23.7
25.0
mmol/l
0.73
22
101
6
9
6.80
2.88
2.3
2.3
627.0
778.7
u/ml
—
6
9
17
71
2.50
2.87
6.9
4.0
24.2
24.9
mmol/l
0.37
17
71
20
91
2.31
2.82
7.9
2.8
1.5
1.2
%
0.41
20
91
9
24
3.85
2.70
1.2
1.4
—
—
—
0
0
30
165
1.94
2.64
10.8
5.7
112.6
121.0
g/l
1.31
30
160
8
20
4.10
2.59
2.9
3.9
—
—
—
0
0
33
189
1.87
2.58
4.1
3.6
—
—
—
0
0
5
7
7.26
2.56
1.0
1.1
—
—
—
0
0
10
34
3.03
2.44
1.2
1.7
—
—
—
0
0
15
64
2.43
2.44
2.1
1.9
—
—
—
0
0
222
2054
2.14
2.43
36.7
12.2
17.2
20.6
mg/l
1.18
208
1572
13
52
2.59
2.40
1.8
1.3
—
—
—
0
0
5
8
6.35
2.38
1.0
1.1
—
—
—
0
0
60
417
1.59
2.35
1.4
1.3
28.5
28.0
iu/ml
0.02
19
146
8
23
3.56
2.29
1.1
1.5
—
—
—
0
0
9
29
3.18
2.25
1.2
1.3
—
—
—
0
0
5
9
5.65
2.22
2.6
1.9
38.4
70.2
ug/l
—
5
9
5
9
5.65
2.22
1.2
1.4
—
—
—
0
0
7
19
3.76
2.16
1.6
1.5
—
—
—
0
0
7
19
3.76
2.16
1.3
1.3
38.3
53.9
u/l
—
7
11
10
37
2.78
2.13
1.5
1.1
—
—
—
0
0
29
171
1.79
2.08
2.9
2.5
52.2
70.8
ml/min/173m2
1.81
15
66
8
27
3.03
1.95
1.5
1.1
—
—
—
0
0
5
11
4.62
1.95
1.0
1.6
15.0
12.2
u/l
—
5
11
14
68
2.12
1.74
1.8
2.3
—
—
—
0
0
6
19
3.21
1.67
1.8
2.2
—
—
—
0
0
19
106
1.86
1.64
13.7
6.0
0.6
0.7
%
0.30
19
106
5
15
3.38
1.53
1.0
1.3
—
—
—
0
0
26
165
1.65
1.48
1.5
3.0
46.0
53.8
u/ml
0.15
26
159
5
16
3.17
1.44
1.0
1.0
—
—
—
0
0
5
16
3.17
1.44
1.0
1.2
—
—
—
0
0
158
1409
1.36
1.43
3.5
3.3
—
—
—
0
0
16
89
1.85
1.41
2.5
1.6
—
—
—
0
0
5
17
2.98
1.36
2.0
2.3
—
—
—
0
0
5
17
2.98
1.36
1.2
1.0
—
—
—
0
0
9
43
2.13
1.32
4.0
3.5
23.7
24.7
mmol/l
—
9
36
9
43
2.13
1.32
1.4
1.5
—
—
—
0
0
18
108
1.72
1.26
14.1
6.0
1.5
1.5
%
0.02
18
108
12
63
1.95
1.25
1.0
1.2
—
—
—
0
0
5
113
0.43
1.16
1.6
1.4
—
—
—
0
0
30
214
1.46
1.06
1.7
3.9
20.4
9.6
ug/l
0.26
22
171
188
1989
0.74
1.04
4.7
4.3
5.5
5.8
mmol/l
2.26
179
1840
186
1733
1.33
1.04
42.9
15.0
14.2
13.6
%
5.09
186
1706
206
1951
1.40
1.02
28.2
11.1
82.4
83.7
ml/min/173m2
0.33
191
1593
9
49
1.87
1.00
1.4
1.5
—
—
—
0
0
179
1663
1.30
0.99
5.2
4.3
14.6
14.6
pmol/l
0.15
172
1533
14
219
0.62
0.96
1.6
1.7
—
—
—
0
0
17
112
1.56
0.87
5.7
7.2
25.1
25.3
mmol/l
0.08
17
105
225
2178
1.56
0.84
37.1
14.0
78.7
71.2
umol/l
1.20
225
2178
67
568
1.25
0.78
1.7
1.6
1.4
1.4
mmol/l
0.04
58
484
0
27
0.00
0.78
0.0
1.3
—
—
—
0
0
7
38
1.87
0.74
1.4
1.1
—
—
—
0
0
14
92
1.55
0.74
1.8
1.5
—
—
—
0
0
216
2090
1.35
0.65
32.4
13.3
139.4
139.8
mmol/l
1.73
216
2034
225
2194
1.44
0.60
26.6
9.8
26.1
24.7
u/l
0.59
225
2120
18
238
0.74
0.56
6.2
5.5
—
—
—
0
0
216
2097
1.31
0.56
33.0
13.3
3.9
3.9
mmol/l
0.14
216
2038
9
61
1.49
0.54
1.1
1.1
—
8.3
—
0
13
8
56
1.44
0.43
1.1
1.9
—
—
—
0
0
9
71
1.28
0.36
2.0
1.3
328.9
310.3
mu/l
—
9
65
53
474
1.15
0.36
1.7
1.5
—
—
—
0
0
5
79
0.63
0.36
1.4
1.8
—
—
—
0
0
7
98
0.71
0.31
2.0
1.6
—
—
—
0
0
15
120
1.27
0.31
1.1
1.0
—
—
—
0
0
10
127
0.78
0.26
1.2
1.3
—
—
—
0
0
9
77
1.18
0.24
1.2
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.9
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
482.9
—
0
7
0
13
0.00
0.21
0.0
1.8
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
39.4
—
0
7
198
1944
1.11
0.20
6.0
5.0
2.1
2.4
mu/l
0.28
189
1801
11
133
0.82
0.20
1.8
1.7
—
—
—
0
0
20
176
1.15
0.18
1.4
1.2
126.6
147.8
iu/ml
—
6
79
207
2041
1.11
0.17
4.8
4.3
1.5
1.6
mmol/l
2.17
199
1892
199
1960
1.09
0.16
4.5
3.9
1.3
1.3
mmol/l
0.33
193
1807
207
2051
1.07
0.09
4.9
4.3
4.5
4.8
mmol/l
4.17
199
1908
8
78
1.03
0.07
1.3
1.1
—
—
—
0
0
187
1888
0.96
0.07
39.2
12.9
36.8
40.1
%
3.48
135
1446
7
85
0.82
0.07
1.6
1.5
—
—
—
0
0
208
2087
0.97
0.01
5.2
4.8
2.6
2.9
mmol/l
3.45
199
1934
25
248
1.01
0.00
1.6
1.9
—
—
—
0
0
25
246
1.02
0.00
3.2
4.5
0.9
2.1
ug/l
2.56
18
222
22
224
0.98
0.00
1.6
1.8
—
—
—
0
0
44
438
1.01
0.00
1.4
1.5
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
1.2
—
0
5
0
7
0.00
0.00
0.0
7.1
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint DRUGADVERS_SYSTEMIC_LUPUS_ERYTHEMAT and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| DRUGADVERS_SYSTEMIC_LUPUS_ERYTHEMAT | 2.507 [2.07, 3.04] | < 0.001 |
| Birth year | 0.993 [0.99, 1.0] | 0.127 |
During the follow-up period (1.1.1998 — 31.12.2019), 239 out of 944 females with DRUGADVERS_SYSTEMIC_LUPUS_ERYTHEMAT died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| DRUGADVERS_SYSTEMIC_LUPUS_ERYTHEMAT | 1.985 [1.37, 2.88] | < 0.001 |
| Birth year | 0.991 [0.98, 1.0] | 0.061 |
During the follow-up period (1.1.1998 — 31.12.2019), 82 out of 199 males with DRUGADVERS_SYSTEMIC_LUPUS_ERYTHEMAT died.
Mortality risk
Mortality risk for people of age
years, who have DRUGADVERS_SYSTEMIC_LUPUS_ERYTHEMAT.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.361% | 0.465% |
| 5 | 1.382% | 2.756% |
| 10 | 3.588% | 6.675% |
| 15 | 6.665% | 12.351% |
| 20 | 11.246% | 20.503% |
Relationships between endpoints
↥Index endpoint: DRUGADVERS_SYSTEMIC_LUPUS_ERYTHEMAT – Drug-induced systemic lupus erythematosus
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data